Effectiveness of combination prophylaxis with cytomegalovirus hyperimmune globulin and acyclovir in the high-risk kidney transplant recipient.
D000212:Acyclovir / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003586:Cytomegalovirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation / Q000276:immunology; D011183:Postoperative Complications / Q000517:prevention & control*; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors
D016756:Immunoglobulins, Intravenous; D000212:Acyclovir